Merck Acquires Late-Stage Congestive Heart Failure Drug With $350 Million NovaCardia Buy
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III program for KW-3092 will continue as laid out by NovaCardia, Merck exec tells “The Pink Sheet” DAILY.
You may also be interested in...
Where Are They Now? Checking In On Four Cardiovascular Start-Ups
It's no secret increasing generic competition and regulatory oversight, combined with the financial challenges of developing a primary care drug, make cardiovascular a tough place for venture-backed biotechs. START-UP takes the pulse of four previously profiled cardiovascular companies -- arca Biopharma, Celladon, NovaCardia and Portola Pharmaceuticals, -- to see what lessons they've learned.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.